BBIO vs GMAB
BridgeBio Pharma, Inc. and Genmab A/S, both Healthcare
Genmab A/S is the larger company at $16B against $14B. Over the past year GMAB returned +31% against +25% for BBIO. The RyuScore puts GMAB ahead, 84 against 7 out of 100.
| Figure | BBIO | GMAB |
|---|---|---|
| Last close | $65.35 | $37.06 |
| Market cap | $14B | $16B |
| 1-year return | +25% | +31% |
| 5-year return | +34% | -15% |
| RyuScoresector-relative, 1–10 | 7/100 | 84/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BridgeBio Pharma, Inc.
Revenue of $244M in Q2 2026, net income null. Its largest reported line is License Services And Royalty, 45% of the disclosed total.
Genmab A/S
Revenue of $12B in H2 2024, net income $5.1B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.